jetcityimage Bernstein started coverage of Eli Lilly ( NYSE: LLY ), Gilead Sciences ( NASDAQ: GILD ) and Amgen ( NASDAQ: AMGN ) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen were based on upside expectations for key assets to generate revenue growth between.
Back to Health Page
